ANVS News and Press, Annovis Bio Inc.

2026-02-12 10:02:57 ET Annovis Bio (NYSE: ANVS) announced that an independent Data and Safety Monitoring Board has issued a positive recommendation supporting continuation of its ongoing pivotal Phase 3 Alzheimer’s disease clinical trial of buntanetap without modificati...

MALVERN, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disea...

2026-01-16 14:42:41 ET More on healthcare stocks XLV Vs. BME: Total Return Or Income, Which Healthcare Strategy Wins? IYH: Elevated Valuations And Slowing Growth Signal Subpar 2026 Returns Aldeyra Therapeutics: Reproxalap's March 2026 FDA Decision Is The Defining Cat...

2025-12-19 09:47:03 ET Annovis Bio (NYSE: ANVS) announced it will initiate an open-label extension study in January 2026 to further evaluate the long-term safety and efficacy of buntanetap in patients with Parkinson disease. The study will provide continued acce...

Enrollment will begin in January 2026 Participants will be treated with buntanetap for 36 months The study aims to enroll 500 patients MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage c...

2025-12-16 09:15:00 ET Annovis Bio (NYSE: ANVS) , a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer disease and Parkinson disease, will host a corporate update webinar followed by a live question-and-answer session. The w...

MALVERN, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's ...

2025-12-03 09:35:00 ET Annovis Bio (NYSE: ANVS) , a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease, said it will present at the 2025 Annual Meeting of the Parkinson Study G...

MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's ...

MALVERN, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's ...